Aplastic Anaemia Associated with Bendamustine Therapy - A Rare Side Effect.

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Cytopenia is a common complication during lymphoma treatment.
• Bendamustine is a chemotherapy agent used for treating lymphomas.
• Drug-induced aplastic anaemia is a rare but severe adverse effect of chemotherapy.

Purpose of the Study:

• To describe a case of aplastic anaemia following bendamustine chemotherapy in a patient with non-Hodgkin's lymphoma.
• To highlight the importance of recognizing hematologic complications associated with bendamustine.
• To emphasize the role of immunosuppressive therapy in managing drug-induced aplastic anaemia.

Main Methods:

• Case report of a 65-year-old female patient with recurrent indolent marginal zone lymphoma.
• Patient received bendamustine and rituximab chemotherapy.
• Diagnosis of aplastic anaemia was made based on pancytopenia and clinical presentation.
• Treatment involved triple immunosuppressive therapy (IST) including anti-thymocyte globulin (ATG).

Main Results:

• The patient presented with neutropenic fever and pancytopenia after bendamustine chemotherapy.
• Aplastic anaemia was diagnosed as a likely consequence of bendamustine chemoimmunotherapy.
• The patient showed a positive response to IST, with normalization of cell counts.
• Anti-thymocyte globulin was effective in treating the bendamustine-induced aplastic anaemia.

Conclusions:

• Bendamustine can induce severe aplastic anaemia, a rare but clinically significant side effect.
• Drug-induced aplastic anaemia requires further research and increased awareness among healthcare professionals.
• Anti-thymocyte globulin is an effective treatment for bendamustine-induced aplastic anaemia by targeting lymphocytes that attack bone marrow.